How we enable success in OSD early development to ensure scalability.

The oral solid dose (OSD) market is $335 billon with a low growth rate of <1 percent over the last 5 years. It is causing a shift in how companies plan and execute the development and manufacturing of OSD drug products. Thermo Fisher Scientific provides a range of early development OSD solutions that can address your small molecule’s unique needs and challenges, while being backed my technical experts and a global network. Leverage our early development services to help:

  • Address formulation challenges such as bioavailability, stability, and solubility
  • Navigate a complex regulatory environment (IND, filing, etc.)
  • Build success in early development to enable commercial success
  • Shortening timelines to get to market quicker
  • Ensuring a robust supply chain within a global network

Learn about our Oral Solid Dose Dosage Forms.

Related Sites

Additional Resources